Anne M Drewry1, Enyo A Ablordeppey1,2, Ellen T Murray3, Catherine M Dalton1, Brian M Fuller1,2, Marin H Kollef4, Richard S Hotchkiss1,5. 1. Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri. 2. Department of Emergency Medicine, Washington University School of Medicine, St. Louis, Missouri. 3. University of Missouri-Columbia School of Medicine, Columbia, Missouri. 4. Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. 5. Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Abstract
INTRODUCTION: Absence of fever is associated with higher mortality in septic patients, but the reason for this is unknown. Immune dysfunction may be a potential link between failure to mount a fever and poor outcomes. The purpose of this study was to evaluate monocyte function and clinical surrogates of immunity (i.e., mortality and acquisition of secondary infections) in febrile and afebrile septic patients. METHODS: Single-center, prospective cohort study of 92 critically ill septic patients. Patients were categorized into febrile (≥38.0°C) and afebrile (<38.0°C) groups based on temperature measurements within 24 hours of sepsis diagnosis. HLA-DR expression and LPS-induced TNF-α production were quantified on days 1-2, days 3-4, and days 6-8 after sepsis diagnosis. A repeated measures mixed models analysis was used to compare these markers between the two groups. RESULTS: Forty-four patients (47.8%) developed a fever within 24 h of sepsis diagnosis. There were no significant differences in HLA-DR expression or LPS-induced TNF-α production between febrile and afebrile patients at any individual time point. However, HLA-DR expression significantly increased between days 1-2 and days 6-8 (median difference 8118 [IQR 1,662, 9,878] antibodies/cell, P = 0.002) in febrile patients, but not in afebrile patients (median difference 403 [-3,382, 3,507] antibodies/cell, P = 0.25). Afebrile patients demonstrated higher 28-day mortality (37.5% vs 18.2%) and increased acquisition of secondary infections (35.4% vs. 15.9%). CONCLUSIONS: Absence of fever is associated with suppressed HLA-DR expression over time, a finding suggestive of monocyte dysfunction in sepsis, as well as worse clinical outcomes.
INTRODUCTION: Absence of fever is associated with higher mortality in septic patients, but the reason for this is unknown. Immune dysfunction may be a potential link between failure to mount a fever and poor outcomes. The purpose of this study was to evaluate monocyte function and clinical surrogates of immunity (i.e., mortality and acquisition of secondary infections) in febrile and afebrile septic patients. METHODS: Single-center, prospective cohort study of 92 critically ill septic patients. Patients were categorized into febrile (≥38.0°C) and afebrile (<38.0°C) groups based on temperature measurements within 24 hours of sepsis diagnosis. HLA-DR expression and LPS-induced TNF-α production were quantified on days 1-2, days 3-4, and days 6-8 after sepsis diagnosis. A repeated measures mixed models analysis was used to compare these markers between the two groups. RESULTS: Forty-four patients (47.8%) developed a fever within 24 h of sepsis diagnosis. There were no significant differences in HLA-DR expression or LPS-induced TNF-α production between febrile and afebrile patients at any individual time point. However, HLA-DR expression significantly increased between days 1-2 and days 6-8 (median difference 8118 [IQR 1,662, 9,878] antibodies/cell, P = 0.002) in febrile patients, but not in afebrile patients (median difference 403 [-3,382, 3,507] antibodies/cell, P = 0.25). Afebrile patients demonstrated higher 28-day mortality (37.5% vs 18.2%) and increased acquisition of secondary infections (35.4% vs. 15.9%). CONCLUSIONS: Absence of fever is associated with suppressed HLA-DR expression over time, a finding suggestive of monocyte dysfunction in sepsis, as well as worse clinical outcomes.
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Ann Intern Med Date: 2007-10-16 Impact factor: 25.391
Authors: Kirsi-Maija Kaukonen; Michael Bailey; David Pilcher; D Jamie Cooper; Rinaldo Bellomo Journal: N Engl J Med Date: 2015-03-17 Impact factor: 91.245
Authors: Jennifer A Muszynski; Ryan Nofziger; Kristin Greathouse; Jyotsna Nateri; Lisa Hanson-Huber; Lisa Steele; Kathleen Nicol; Jonathan I Groner; Gail E Besner; Corey Raffel; Susan Geyer; Osama El-Assal; Mark W Hall Journal: Shock Date: 2014-10 Impact factor: 3.454
Authors: Maryse A Wiewel; Matthew B Harmon; Lonneke A van Vught; Brendon P Scicluna; Arie J Hoogendijk; Janneke Horn; Aeilko H Zwinderman; Olaf L Cremer; Marc J Bonten; Marcus J Schultz; Tom van der Poll; Nicole P Juffermans; W Joost Wiersinga Journal: Crit Care Date: 2016-10-14 Impact factor: 9.097
Authors: Anne M Drewry; Enyo A Ablordeppey; Ellen T Murray; Evan R Beiter; Andrew H Walton; Mark W Hall; Richard S Hotchkiss Journal: Crit Care Date: 2016-10-20 Impact factor: 9.097
Authors: Anne M Drewry; Nicholas M Mohr; Enyo A Ablordeppey; Catherine M Dalton; Rebecca J Doctor; Brian M Fuller; Marin H Kollef; Richard S Hotchkiss Journal: Crit Care Med Date: 2022-02-07 Impact factor: 9.296
Authors: Kenneth E Remy; Monty Mazer; David A Striker; Ali H Ellebedy; Andrew H Walton; Jacqueline Unsinger; Teresa M Blood; Philip A Mudd; Daehan J Yi; Daniel A Mannion; Dale F Osborne; R Scott Martin; Nitin J Anand; James P Bosanquet; Jane Blood; Anne M Drewry; Charles C Caldwell; Isaiah R Turnbull; Scott C Brakenridge; Lyle L Moldwawer; Richard S Hotchkiss Journal: JCI Insight Date: 2020-09-03
Authors: Nathaniel Bonfanti; Emily Gundert; Anne M Drewry; Kristina Goff; Roger Bedimo; Erik Kulstad Journal: PLoS One Date: 2020-12-01 Impact factor: 3.240
Authors: Emily M Evans; Rebecca J Doctor; Brian F Gage; Richard S Hotchkiss; Brian M Fuller; Anne M Drewry Journal: Shock Date: 2019-08 Impact factor: 3.454